Comparison of rapidity of coronary recanalization in men with tenecteplase versus alteplase in acute myocardial infarction

Safety and efficacy of tenecteplase versus alteplase in acute coronary syndrome: a systematic review and meta-analysis of randomized trials

“…Four studies [8, 15–17] including a total of 18,208 patients met the inclusion criteria. One study was Asian [16], two North-American [15, 17] and one multicentric [8]. All studies compared alteplase to tenecteplase in acute myocardial infarction (STEMI).…”

“…No study comparing alteplase versus tenecteplase in pulmonary embolism was found. Three of the four studies [8, 16, 17] compared alteplase and tenecteplase at equal doses (TNK: 30–50-mg single bolus weight-adjusted, t-PA: 15-mg bolus, followed by a 0.75-mg/kg (up to 50-mg) infusion over 30 min, followed by 0.50-mg/kg (up to 35-mg) infusion over 60 min). In the remaining study [15], tenecteplase was randomly administered at doses of 30, 40 or 50 mg.…”

“…Three studies [8, 16, 17] including 17,325 patients reported on major bleeding. The reported incidence of major bleeding was 4.8% (399/8651) in the tenecteplase group and 5.8% (507/8674) in the alteplase group (Figure 2).…”

“…Three studies [15–17] reported on the rate of reperfusion. In the study by Liang et al [16] TIMI grade flow 3 at 90 min was similar in patients treated with TNK-tPA (68.4%) or tPA (66.7%, p = 1.00).…”

The potential of erythropoietin for conferring cardioprotection complementing reperfusion

“…Sheikh Hamdan Award, we have initiated a proof of concept trial (the Dubai/Vermont study) in patients with ST elevation myocardial infarction (STEMI), in whom reperfusion will be induced within 6 h after the onset of chest pain as was the case in our earlier collaborative studies [20,21]. We plan to study 250 patients with STEMI randomized to receive intravenous EPO, 30 000 IU, immediately after onset of administration of tenecteplase (TNK) or to treatment with TNK without EPO.…”